IL6 and rheumatoid arthritis: Studies compared the efficacy of baricitinib and methotrexate monotherapy in pain management in early RA and found that baricitinib, along with other JAKis, is more effective in advanced RA patients than tumor necrosis factor blockers or interleukin-6 inhibitors [83,85,86].